12Jan
Sanofi to Acquire Kymab for up to $1.45 Billion
Sanofi announced that it has entered into an agreement to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones. The acquisition will give Sanofi full global rights to Kymab’s KY1005, which binds to OX40-Ligand and has the potential to treat a wide variety of...
By:
Goodwin
Related
Decision highlights the need to coordinate document production in parallel cross-border merger contr...
Read More >
In the field of labor relations, there exist some rare occurrences, things that happen so seldom tha...
Read More >
All the holiday party information that's fit to print, as we enter this most dangerous season for em...
Read More >
Recently, the United States Supreme Court invited the U.S. Solicitor General of the Department of Ju...
Read More >
On December 20, 2019, Congress enacted the SECURE Act as part of the Further Consolidated Appropriat...
Read More >
Employers often allow employees to donate leave to co-workers who are experiencing medical emergenci...
Read More >